Skip to main content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by

Experts reflect on their highlights from ESMO 2018

ESMO flags

Hisham Mehanna, Ricardo Alvarez and Massimo Christofanilli, and Thomas Seufferlein discuss their ESMO 2018 highlights in head & neck, breast, and gastrointestinal cancer, respectively (7:42).

STAMPEDE suggests radiation OS benefit for select metastatic prostate cancer patients

Man receiving radiotherapy

The latest results from the STAMPEDE trial do not show an additional overall survival benefit with radiotherapy for men undergoing androgen deprivation therapy with or without docetaxel for newly diagnosed metastatic prostate cancer.

Neoadjuvant pembrolizumab ‘worthwhile’ for some invasive bladder cancers

IV drip_patient's hand

Neoadjuvant pembrolizumab therapy results in an “impressively high” pathologic complete response rate among patients with programmed cell death ligand 1-positive muscle-invasive bladder carcinoma, researchers say.

Adding plasma NGS testing to routine NSCLC management could aid targeted therapy delivery

Multi-well plate_pipette

Plasma-based next-generation sequencing may help to identify therapeutically targetable mutations in patients with metastatic non-small-cell lung cancer, suggests research published in JAMA Oncology.


medwireNews was in Munich for the ESMO 2018 Congress. Click through for all the research news and expert interviews.

Latest headlines

19-11-2018 | Checkpoint blockade | News

Clinically important safety differences found among immune checkpoint inhibitors

A network meta-analysis has ranked the safety of immune checkpoint inhibitors in cancer treatment, with atezolizumab revealed to have the best general safety profile.

15-11-2018 | Renal cell carcinoma | News

Genomic annotation improves MSKCC risk model for renal carcinoma

Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.

13-11-2018 | Non-small cell lung cancer | News

Lorlatinib shows promising activity against ALK-positive advanced NSCLC

Patients with ALK-positive advanced non-small-cell lung cancer respond to the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib irrespective of previous ALK tyrosine kinase inhibitor treatment status, phase II study data show.

In depth

Researcher comment: COMPARE study

Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research

27-04-2018 | Adolescents and young adults | Feature | Article

ACCELERATE-ing access to drugs for adolescents with cancer

medwireNews spoke to Miranda Fidler, from the International Agency for Research on Cancer, and Simon Davies, from Teen Cancer America, about the ACCELERATE working group's proposal to improve adolescent patients’ access to new cancer drugs.

Click for the accompanying news story

ALL and infection: Unpicking the connection

Professor Mel Greaves (Institute of Cancer Research, London, UK) discusses his proposed theory for the etiology of childhood acute lymphoblastic leukemia, in which early microbial exposure plays a key role.

image credits